Browsing by Author "Sakin, Abdullah"
Now showing items 1-4 of 4
-
The conversion ofRASstatus in metastatic colorectal cancer patients after first-line biological agent treatment
Arıcı, Serdar; Hamdard, Jamshid; Sakin, Abdullah; Şengiz Erhan, Selma; Atçı, Muhammed Mustafa; Cekin, Ruhper; Saka, Burcu; Köse, Emin; Saydam, Tuba; Geredeli, Çağlayan; Cihan, Şener; Bilici, Ahmet (Wiley, 2021)Aim The aim was to investigate theRASdiscordance between initial and recurrent metastasectomy specimens in metastatic colorectal cancer (mCRC) patients treated with chemotherapy (CT) plus biological agents in a first-line ... -
Effect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study
Atcı, Muhammed Mustafa; Akagündüz, Baran; Demir, Metin; Dönmez Yılmaz, Binnur; Akın Telli, Tuğba; Can, Orçun; Çil, İbrahim; Göktaş Aydın, Sabin; Özyurt, Neslihan; Önder, Arif Hakan; Selvi, Oğuzhan; Sakin, Abdullah (NLM (Medline), 2022)INTRODUCTION: A significant proportion of cervical cancer (CC) patients are diagnosed at a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the cornerstone of treatment for patients with locally advanced CC. ... -
Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group
Akagündüz, Baran; Akın Telli, Tuğba; Yıldırım, Hasan Çağrı; Göksu, Sema Sezgin; Demir, Nazan; Hafızoğlu, Emre; Özer, Muhammet; Çevik, Gökçen Tuğba; Sakin, Abdullah; Göktaş Aydın, Sabin; Şengül Samancı, Nilay; Özyurt, Neslihan; Atçı, Muhammed Mustafa; Ayhan, Murat; Turan, Merve; Sarıyar, Nisanur; Karaçin, Cengiz; Kılıçkap, Saadettin; Paydaş, Semra; Doğan, Mutlu (Akad Doktorlar Yayinevi, 2021)Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and encompass a heterogeneous group of tumors with limited multimodality treatment options. Surgical resection with negative ... -
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes
Esin, Ece; Çakmak Öksüzoǧlu, Berna; Bilici, Ahmet Erkan; Çiçin, İrfan; Köstek, Osman; Kaplan, Mehmet Ali; Aksoy, Sercan; Aktaş, Burak Yasin; Özdemir, Özlem; Alacacıoğlu, Ahmet; Çabuk, Devrim; Sümbül, Ahmet Taner; Sakin, Abdullah; Paydaş, Semra; Yetişir, Ersin; Er, Özlem; Korkmaz, Taner; Yıldırım, Nilgün; Şakalar, Teoman; Demir, Hacer; Artaç¸, Mehmet; Karaaǧaç, Mustafa; Harputluoǧlu, Hakan; Bilen, Ebru; Erdur, Erkan; Deǧirmencioǧlu, Serkan; Aliyev, Altay; Çil, Timuçin; Olgun, Polat; Başaran, Gül Atalay; Gümüşay, Özge; Demir, Atakan; Tanrıkulu, Eda; Yumuk, Perran Fulden; İmamoğlu, İnanç; Oyan, Başak; Çetin, Bülent Eren; Haksöyler, Veysel; Karadurmuş, Nuri; Ertürk, İsmail; Evrensel, Türkkan; Yılmaz, Hasan; Beypınar, İsmail; Koçer, Murat; Pilancı, Kezban Nur; Şeker, Mesut Metin; Ürün, Yüksel; Yıldırım, Nuriye O.; Eren, Tülay; Demirci, Umut (Springer, 2019)PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ...